CA 19-9 in non-neoplastic liver diseases. A clinical and laboratory study
| Autor: | Ruibal A, Jose Genollá, Julio Collazos |
|---|---|
| Rok vydání: | 1992 |
| Předmět: |
Adult
Liver Cirrhosis Male Pathology medicine.medical_specialty Adolescent Non neoplastic Bilirubin Clinical Biochemistry Disease Biochemistry Basal (phylogenetics) chemistry.chemical_compound Cholestasis Reference Values medicine Humans Antigens Tumor-Associated Carbohydrate Aged Tumor marker Aged 80 and over business.industry Liver Diseases Biochemistry (medical) General Medicine Middle Aged Alkaline Phosphatase medicine.disease chemistry Alkaline phosphatase Female CA19-9 business |
| Zdroj: | Clinica Chimica Acta. 210:145-151 |
| ISSN: | 0009-8981 |
| DOI: | 10.1016/0009-8981(92)90053-s |
| Popis: | CA 19-9 is a tumor marker with frequent false-positive results in pancreatic and hepatobiliary diseases. This study was carried out to evaluate the behaviour of CA 19-9 in 159 patients with benign diffuse hepatic disease, 85 cirrhotics and 74 noncirrhotics, who underwent a thorough clinical and laboratory evaluation. CA 19-9 was correlated with numerous clinical and biochemical features of liver diseases: bilirubin and alkaline phosphatase activity were the most reliable predictors of the CA 19-9 concentrations. There were abnormal concentrations of CA 19-9 in 34.6% of the 159 patients and in 47.1% of the 85 cirrhotics. Because of the large number of abnormal values and the high concentrations attained in some of them, the cut-off used in patients with diffuse hepatic disease needs to be set at more than twice the basal level, thus allows only 10% of false positives. Even higher values are required for cirrhotic or icteric patients. The results indicate that cholestasis plays an important role in causing the raised CA 19-9 in these patients, although there were also abnormal concentrations in normobilirubinemic patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|